Apart from OSCC, RANK and RANKL signaling is also known to contribute to bone invasion or bone metastasis in myeloma, breast, hepatocellular, lung and prostate cancer [13,14,15,16,17,18,19,20,21]. Here, TNFRSF11A is linked to prostate cancer.